SCHEMBL3451695

SCHEMBL3451695

CC(C)c1ccc(-c2ccnc(NCc3cccs3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.50
LMNA P02545 8/20 0.50
KDM4E B2RXH2 4/20 0.50
CYP1A2 P05177 8/20 0.46
CYP3A4 P08684 8/20 0.46
CYP2D6 P10635 8/20 0.46
CYP2C19 P33261 8/20 0.46
CLK4 Q9HAZ1 7/20 0.46
MAPT P10636 4/20 0.46
ALOX15 P16050 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
HSD17B10 Q99714 3/20 0.46
TP53 P04637 3/20 0.46
USP2 O75604 2/20 0.46
CLK1 P49759 2/20 0.46
HIF1A Q16665 1/20 0.46
HPGD P15428 3/20 0.45
PTGS2 P35354 3/20 0.45
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24334901 0.81 PTGS2 (0.68) ALDH1A1LMNAKDM4EMAPTSMN1; SMN2
SCHEMBL3453202 0.80 CYP1A2 (0.71) ALDH1A1LMNACYP1A2CYP3A4CYP2D6
SCHEMBL3452385 0.79 LMNA (0.48) ALDH1A1LMNAKDM4ECYP1A2CYP3A4
SCHEMBL3452192 0.74 CYP1A2 (0.56) ALDH1A1LMNAKDM4ECYP1A2CYP3A4
SCHEMBL27114180 0.74 CLK4 (0.43) ALDH1A1LMNAKDM4ECYP1A2CYP3A4
SCHEMBL14849565 0.74 MAPT (0.63) ALDH1A1LMNAKDM4ECYP3A4CYP2D6
SCHEMBL13109653 0.72 TRPM8 (0.42) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL27909931 0.72 HDAC3 (0.58) ALDH1A1LMNAKDM4ECYP1A2CYP3A4
Hydrochloric Acid SCHEMBL3451787 0.71 TRPM8 (0.42) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL3451432 0.70 KDM4E (0.51) ALDH1A1LMNAKDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
EP-1753735-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS Transtech Pharma, Inc. (US) 2007-02-21 EP disclosed
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use VTVX HOLDINGS I LLC 2005-11-24 US disclosed
WO-2005103022-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS TRANSTECH PHARMA, INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use MC5R, MC3R, MC4R ALDH1A1 1513/4885LMNA 3752/4885KDM4E 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.